Six updates in ovarian cancer (September is Ovarian Cancer Awareness Month) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, September 09, 2016

Six updates in ovarian cancer (September is Ovarian Cancer Awareness Month)

medical news September 9, 2016
HemOnc Today presents six updates in gynecological cancer treatment and surveillance methods.
  • The FDA granted priority review to rucaparib (Clovis Oncology) for the treatment of advanced ovarian cancer in patients with germline or somatic BRCA–mutated tumors. Read more.
  • The use of power morcellation among women undergoing minimally invasive hysterectomy significantly decreased in the wake of an FDA recommendation against its use; however, the use of abdominal hysterectomy increased during this period. Read more.
  • The FDA granted orphan drug designation to ZW25 and ZW33 for the treatment of ovarian cancer, according to the agents’ manufacturer. Read more.
  • Neoadjuvant chemotherapy is the optimal first-line treatment for certain women with newly diagnosed advanced ovarian cancer, according to a joint clinical practice guideline from ASCO and the Society of Gynecologic Oncology. Read more.
  • Cancer antigen 125 tests and CT scans are routinely used for surveillance of patients with ovarian cancer despite a lack of proven benefit, according to results of a prospective cohort study. Read more.
  • The FDA issued a warning to alert patients and physicians that screening tests for ovarian cancer have been found unreliable and could lead to false diagnoses. Read more.


Post a Comment

Your comments?